Mondobiotech Holding AG Company presentation

More documents

Recommendations

Info

Management Ruggero Gramatica CEO Dorian Bevec CSO Paolo Barbieri CFO Maria Teresa D’Antonangelo Bühlmann Corporate Affairs Business Support Ruggero has extensive experience in startups having successfully delivered growth and expansion to 6 companies in the technology arena worldwide. He brings strategic leadership and operational expertise. He has masterminded the bio-mathematical model which supports the company’s research approach and he remains academically involved in research activity in the field of Applied Mathematics with Kings College, London. Ruggero attended ‘Politecnico di Milano’ and obtained a BS-Eng and an MSc in Electrical Engineering and holds an MBA from the University of Chicago. Dr. Habil. Dorian Bevec is Mondobiotech’s Chief Scientific Officer and a co-founder of Mondobiotech. Dorian Bevec holds a Ph.D. (Dr. rer. nat.) from the Ludwig-Maximilians University of Munich and a habilitation (Venia Docendi) from the University of Vienna. Prior to that, Dorian had worked as Head of Molecular Biology and project team leader at the Sandoz Research Institute in Vienna for ten years and previously at Axxima AG in Martinsried. Paolo brings over 25 years of senior management, financial and capital market experience. Prior to joining mondoBIOTECH, he was Deputy CEO and Chief Investment Officer at Pioneer Alternative Investments, he has successfully founded and managed Akros HFR Alternative Investments and has been Managing Director and Head of Equity Capital Markets at Banca Akros. Maria Teresa is an attorney-at-law and is admitted to bar since 2003. She gained an in-depth knowledge and experience in international commercial law and intellectual property law, with a specialization in patents and copyright. Before joining Mondobiotech in 2005, she worked as associate in the law-firm Freshfield Bruckhaus Deringer in Milan and Paris and from 2001 until 2005 as senior associate in the law firm Avvocati Associati in Milan. 4
Board of Directors Robert Edward Patterson Chairman MD, Peninsula Venture Graf Francis von Seilern-Aspang CEO Industrie u. Finanzkontor Prinz Michael von und zu Liechtenstein Vice-Chairman Marc Häsler Etude Häsler, H&B Law Ruggero Gramatica CEO mondoBIOTECH Vincenzo Romano MC Consulting Suisse Prof. Dr. Michael A. Keller Stanford University 5
Page 1 and 2: Mondobiotech Holding AG Company pre
Page 3: mondoBIOTECH at a glance • Headqu
Page 7 and 8: Our approach to drug discovery •
Page 9 and 10: Introduction to the Search&Match me
Page 11 and 12: The Model • Knowledge from litera
Page 13 and 14: The Search and Match Software Platf
Page 15 and 16: Match • Any path through the know
Page 17 and 18: Match - a multi-technique approach
Page 19 and 20: Bio-Mathematical Technology Platfor
Page 21 and 22: Match - Project DK-0112-01 21
Page 23 and 24: Match - Project DK-1001-01 23
Page 25 and 26: MPC Validation: the mondoBIOTECH Co
Page 27 and 28: Set up of new projects PROJECT SET
Page 29 and 30: Intellectual Property Strategy & Cu
Page 31 and 32: mondoBIOTECH’s IP Strategy Two in
Page 33 and 34: mondoBIOTECH’s IP Strategy: Two I
Page 35 and 36: Orphan Drug Designations 10 Granted
Page 37 and 38: Why Peptides Peptides characteristi
Page 40 and 41: Diversifying the Risk in Drug Disco
Page 42 and 43: Current Pipeline DasKloster 1000-01
Page 46: Scientific Snapshot Information: DK
Page 49 and 50: Scientific Snapshot Information: DK
Page 51 and 52: Products licensed DasKloster 1001-0
Page 53 and 54: Licensed Products • Aviptadil pla
Page 55:
mondoBIOTECH holding AG DasKloster
show all

Mondobiotech Holding AG Company presentation

Create successful ePaper yourself

Delete template?

Save as template?